Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarkers of response to proteasome inhibitors

A proteasome inhibitor and labeling technology, which is applied in the fields of peptide/protein components, biochemical equipment and methods, microbial measurement/inspection, etc., can solve the problem that patients cannot bear the time of trial and error selection of treatment plans, etc.

Active Publication Date: 2014-09-10
TAKEDA PHARMA CO LTD
View PDF107 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Many patients cannot afford the time of trial-and-error choice in treatment options

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers of response to proteasome inhibitors
  • Biomarkers of response to proteasome inhibitors
  • Biomarkers of response to proteasome inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0226] xenograft

[0227] Xenografts with names beginning with PHTX were obtained at Millennium Pharmaceuticals, Inc. as follows: Tumors obtained from patients were obtained through the Cooperative Human Tissue Network and the National Disease Research Exchange. Research Interchange). Within 24 hours of surgery, tumors were implanted in 4 SCID-NOD mice. Tumors were serially passaged 2-3 times in SCID-NOD mice to confirm growth, and material was stored in liquid nitrogen to retrieve tumors for future use. Tumors were further passaged into a large number of NCr-nude and / or CB17 SCID mice for study as MLN2238 listed in Table 3. Tumors taken from patients were histologically characterized by H&E staining, and DNA was prepared from frozen sections of passaged tumors for mutational analysis by Signo.

[0228] Table 3. Source information for primary human tumors

[0229]

[0230] Xenografts whose name begins with LXF were obtained from Oncotest GmbH, Freiburg im Breisgau, Ge...

example 2

[0255] Example 2. Glucose Transporter

[0256] In general, tumor cells exhibit higher levels of glucose metabolism than normal cells (reviewed in Adkula et al. (2012) 24:650-654). KRAS mutant colorectal cancer cells display higher glucose uptake and glycolysis and better growth and survival under nutrient stress than wild-type cells (Yun et al. 2009 Science 325:1555). The study identified GLUT1 (glucose transporter 1) as upregulated in KRAS mutant colorectal cancer cells.

[0257] Most tumor cell lines are sensitive to MLN2238 in vitro under standard culture conditions using high glucose, making it difficult to distinguish between sensitive and resistant cell lines in vitro. However, under in vivo conditions, less glucose is available. Glucose transporter expression was analyzed by Western blotting of tumor cell lines listed in Table 5 that were not treated with MLN2238 but grown in mice as xenografts or in culture. Proteins were prepared from xenograft tumor samples or c...

example 3

[0258] Example 3. Other Sequencing Methods and General Procedures

[0259] Sanger sequencing method. PCR amplification was performed using optimized cycling conditions on a gene-to-exon basis. Primer extension sequencing was performed using Applied Biosystems BigDye version 3.1. Reactions were then run on an Applied Biosystems 3730xl DNA Analyzer. Sequencing base calling was performed using KBTM base caller (Applied Biosystems). Somatic mutation calls were determined by Mutation Measurer (SoftGenetics) and manually confirmed by aligning the sequencing data to the corresponding reference sequence using Seqman (DNASTAR).

[0260] Next-generation sequencing (NGS) methods. Directed NGS using the Illumina platform (Illumina Inc., San Diego, CA) was used to confirm and identify low frequency mutations in the markers. Primer pairs were designed to amplify coding exons. PCR products were quantified using PicoGreen assay and combined in equimolar ratios for each sample. The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are markers associated with sensitivity to treatment with proteasome inhibitors. Sensitivity is observed when RAS gene is wild type in tumor cells. Compositions and methods are further provided to assess markers of marker genes to predict outcome of treatment using proteasome inhibitors to patients having a solid tumor, such as a lung tumor or a colon tumor.

Description

[0001] Related applications [0002] This application claims priority to US Provisional Patent Application Serial No. 61 / 558,474, filed November 11, 2011, and US Provisional Patent Application Serial No. 61 / 721,818, filed November 2, 2012. The entire contents of the aforementioned applications are incorporated herein by reference. [0003] sequence listing [0004] This application contains a Sequence Listing filed herewith in an electronically readable format. The electronic sequence listing file was created on November 8, 2012 and is named "sequencelisting.txt" and is 26.4kb (27,099 bytes) in size. The entire contents of the sequence listing in the electronic sequencelisting.txt file are incorporated herein by this reference. Background technique [0005] A cell becomes a cancer cell when the genotype or phenotype of the cell changes in such a way that uncontrolled growth unconstrained by the normal tissue environment ensues. Mutation, amplification, deletion, overexp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/69A61P35/00A61K38/00C12Q1/68C12N15/11G16H10/40G16H70/60
CPCA61K31/69A61K38/06C12Q1/6886C12Q2600/106C12Q2600/158C12Q2600/156A61P35/00G06Q40/08G16H70/60G16H10/40G01N33/5011
Inventor 阿里森·伯格尼比迪塔·查托帕蒂亚雅艾瑞克·M·凯尼格
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com